CMS Secures IND Approval for Novel siRNA Obesity Drug Targeting INHBE
Event summary
- CMS's INHBE-targeting siRNA drug CMS-D008 received IND approval from NMPA on March 4, 2026 for clinical trials in overweight/obese individuals.
- CMS-D008 is a subcutaneous injection that reduces hepatic INHBE expression, lowering Activin E protein levels to block fat accumulation.
- Preclinical studies showed CMS-D008 effectively reduced fat mass while preserving lean mass with a good safety profile.
- CMS plans to combine CMS-D008 with its GLP-1R/GCGR dual agonist CMS-D005 for comprehensive weight-loss solutions.
The big picture
CMS's IND approval for CMS-D008 positions it in the competitive obesity treatment market, which is projected to impact nearly 3 billion adults globally by 2025. The drug's novel mechanism targeting INHBE offers a potential alternative to existing GLP-1RAs, focusing on genetic-level fat reduction. CMS's strategy to combine CMS-D008 with its existing pipeline asset CMS-D005 could enhance its competitive edge in the metabolic disease space.
What we're watching
- Clinical Trial Progress
- The pace at which CMS initiates and completes clinical trials for CMS-D008 will determine its market potential.
- Combination Therapy
- Whether CMS can successfully combine CMS-D008 with CMS-D005 to create a more effective obesity treatment regimen.
- Regulatory Landscape
- How NMPA's approval process and requirements will impact the timeline and costs of bringing CMS-D008 to market.
Related topics